Apogee Therapeutics, Inc.
NASDAQ:APGEBiotechnology
+$1.05 today
- Market cap
- $8.36B
- Beta
- 0.62
- P/E (TTM)
- -22.7
- EPS (TTM)
- -$3.94
Volume 0.00M
Average 0.97M
APGE Net Change in Cash
Combined operating, investing, financing, and currency effects on the cash balance during the period.
Apogee Therapeutics, Inc.NASDAQ: APGE
Net Change in Cash · Q2 FY2026 · quarter ended Jun 2026
Net change in cash turns negative
Q2 FY2026 net change in cash was -$346.23M, compared with $17.28M a year earlier. Trailing-twelve-month net change in cash was -$18.92M.
Context
- Net change in cash increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly net change in cash holds near -$346.23M or moves back toward the trailing-twelve-month quarterly average of -$4.73M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Net Change in Cash history
USD · from the cash flow
- Latest · FY2025
- (10.53M) USD
- Year-over-year change
- -144.9%
| Period | Period end | Net Change in Cash | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (10.53M) | -144.9% |
| FY2024 | 2024-12-31 | 23.47M | +170.5% |
| FY2023 | 2023-12-31 | (33.28M) | -121.9% |
| FY2022 | 2022-12-31 | 151.89M | — |
Net Change in Cash vs competitors
How APGE compares with its peers on the latest reported figures
- Peers report in different currencies, so net change in cash is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -89.7% is the 7th highest of 10, against a peer median of +174.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
AAPGAscentage Pharma Group International | FY2025 | CN¥302.68M CNY | +308.8% | — | 54.2% |
| LTM Sep 2026 | $181.76M USD | +200.8% | +85.0% | 13.4% | |
| LTM Jun 2026 | $135.7M USD | +753.7% | — | — | |
| LTM Jun 2026 | $124.74M USD | -222.0% | +73.0% | 27.7% | |
IRONDisc Medicine, Inc. | LTM Sep 2026 | $60.66M USD | +16.7% | — | — |
| LTM Mar 2026 | $46.18M USD | +174.8% | — | 6.9% | |
| LTM Mar 2026 | $42.07M USD | +222.1% | +16.8% | — | |
| LTM Sep 2026 | $21.95M USD | -230.0% | — | — | |
| LTM Jun 2026 | $18.92M USD | -89.7% | — | — | |
| LTM Sep 2026 | $16.9M USD | -1074.5% | — | 274.1% | |
| Peer median (excluding APGE) | — | +174.8% | +73.0% | 27.7% | |
Competitors are the stored peer set for APGE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (39.79M) | (83.99M) | (182.15M) | (255.84M) |
| Depreciation & Amortization | 0 | 0 | 189K | 1.42M |
| Deferred Income Tax | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.14M | 6.1M | 23.33M | 46.28M |
| Change in Working Capital | 9.82M | 6.11M | (2M) | (15.48M) |
| Accounts Receivables | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 |
| Accounts Payables | 418K | 1.61M | (1.07M) | 150K |
| Other Working Capital | 9.4M | 4.49M | (930K) | (15.63M) |
| Other Non-Cash Items | 11.4M | (2.98M) | (10.55M) | (3.82M) |
| Operating Cash Flow | (16.43M) | (74.76M) | (171.17M) | (227.45M) |
| Capital Expenditures | 0 | (167K) | (1.15M) | (5.15M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (303.74M) | (649.45M) | (642.3M) |
| Sales of Investments | 0 | 30M | 350.14M | 467.87M |
| Other Investing Activities | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | (273.91M) | (300.46M) | (179.57M) |
| Debt Repayment | 0 | 0 | 0 | 0 |
| Common Stock Issued | 168.32M | 315.39M | 493.48M | 396.49M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 1.63M | 0 |
| Financing Cash Flow | 168.32M | 315.39M | 495.11M | 396.49M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 |
| Net Change in Cash | 151.89M | (33.28M) | 23.47M | (10.53M) |
| Free Cash Flow | (16.43M) | (74.93M) | (172.33M) | (232.6M) |
Apogee Therapeutics, Inc.
NASDAQ:APGE
Intrinsic Alpha fair value
Locked
Current Price
$135.07
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.